bioMerieux (FR:BIM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
bioMérieux has announced FDA 510(k) clearance for its VITEK® REVEAL™ antibiogram system, which provides rapid antibiotic sensitivity tests crucial for treating sepsis and combating antibiotic resistance. This innovative technology delivers results from positive blood cultures within approximately 5.5 to 6 hours, enabling same-day therapeutic decisions. The clearance marks a significant milestone for bioMérieux, enhancing its comprehensive solutions in the diagnostics market and supporting the proper use of antibiotics.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.
